1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1600
  5. Art Unit 1609
  6. Examiner Brown

Examiner Brown Mindy G

1609-BROWN-MINDY-G

Employment Information

Art Unit:1609 — Unknown
Group:1600 — UNKNOWN
Classes: 435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
424 — Drug, bio-affecting and body treating compositions
Phone:
Email:None
Location:None

Grant Rate and Difficulty Ranking

80
3-Year Grant rate: 50% over 103 cases
Difficulty: Harder
Difficulty Percentile: 80th

With Examiner Brown, you have a 50% chance of getting an issued patent by 3 years after the first office action. Examiner Brown is a harder examiner and in the 80th percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Brown, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1609

Examiner Brown's grant rate is lower than that of Art Unit 1609 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Brown 1.7
Art Unit 1609 0.0

Interview Benefit

Grant Rate without Interview

Examiner Brown has granted 38 of 81 cases without any applicant-requested interviews for a grant rate of 47%.

Grant Rate with Interview

Examiner Brown has granted 13 of 22 cases with at least one applicant-requested interview for a grant rate of 59%.

Interview Benefit

With Examiner Brown, conducting an interview increases your chance of getting a patent granted by 26%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
15777182 Stabilized Reagents For Genome Modification Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
16814591 Compositions And Methods For Target Nucleic Acid Modification Abandoned View
16243207 Methods To Predict Clinical Outcome Of Cancer Abandoned View
15555479 Multiple Vector System And Uses Thereof Abandoned View
15146653 Generation Of Layered Transcriptional Circuitry Using Crispr Systems Abandoned View
15751913 Regulatory Protein Deficient Trichoderma Cells And Methods Of Use Thereof Abandoned View
16001616 Thyroid Cancer Diagnostics Abandoned View
15590961 Methods And Compositions For Treating Cancer Abandoned View
16039150 Methods And Compositions For Genetically Manipulating Genes And Cells Abandoned View
15499841 One Pot Assembly Abandoned View
16144282 Manufacturing Methods For Production Of Rna Transcripts Abandoned View
15824023 Capsid-Modified, Raav3 Vector Compositions And Uses In Gene Therapy Of Human Liver Cancer Patented View
15820425 Chimeric Dna:rna Guide For High Accuracy Cas9 Genome Editing Abandoned View
16006002 Methods And Compositions For Rapid Assembly Of Genetic Modules Abandoned View
15305453 Method Of Obtaining A Polyepitopic Protein And Polyepitopic Dna Vector Patented View
15905817 Programmable Modification Of Dna Abandoned View
16142501 Methanol-Utilizing Yeast-Derived Novel Protein And Method For Producing Protein Of Interest Using Same Abandoned View
15696246 Method For Rna-Guided Endonuclease-Based Dna Assembly Abandoned View
15611490 Engineered Nucleic Acids And Methods Of Use Thereof Abandoned View
15752370 Aav6 Vectors For Immunotherapy Abandoned View
15655279 Biologically Active C-Terminal Arginine-Containing Peptides Abandoned View
16041703 Compositions Of Mosquitocidal Clostridial Proteins And Methods Of Use Abandoned View
15855543 Light-Activated, Calcium-Gated Polypeptide And Methods Of Use Thereof Abandoned View
15407215 Synthetic Yeast Agglutination Abandoned View
15113656 Methods And Compositions For Sequences Guiding Cas9 Targeting Patented View
15884618 Complexes Of Rna And Cationic Peptides For Transfection And For Immunostimulation Abandoned View
15408320 Complexes Of Rna And Cationic Peptides For Transfection And For Immunostimulation Abandoned View
15719815 Alternative Splice Variant Patterns Of Human Telomerase Reverse Transcriptase (Htert) In Thyroid Tumors To Distinguish Benign From Malignant Patented View
15229308 Two Plasmid Mammalian Expression System Patented View
15762316 Modification Of The Dystrophin Gene And Uses Thereof Abandoned View
16060753 Bacterial Colicin-Immunity Protein Protein Purification System Patented View
15415276 Sandwich Assays In Droplets Patented View
15566244 Production Of Non-Caloric Sweeteners Using Engineered Whole-Cell Catalysts Patented View
15764070 Modified Bacterial Protein Expression System Patented View
16004992 Recombinant Production Method Patented View
15624077 Hic: Method Of Identifying Interactions Between Genomic Loci Patented View
15996892 B4galt1 Cdna Variants And Compositions Comprising The Same Patented View
15055034 Host Cell Protein Modification Abandoned View
15072978 Methods, Cells & Organisms Abandoned View
15326103 Chimeric Polynucleotides Abandoned View
16582269 Recombinant Type I Crispr-Cas System Patented View
14909008 Adeno-Associated Viral (Aav) Vectors Useful For Transducing Adipose Tissue Patented View
14903682 Methods And Compositions For Interference With Dna Polymerase And Dna Synthesis Patented View
15905390 Biomarkers In Peripheral Blood Mononuclear Cells For Diagnosing Or Detecting Lung Cancers Abandoned View
15384029 Method For Rapidly Screening Microbial Hosts To Identify Certain Strains With Improved Yield And/or Quality In The Expression Of Heterologous Proteins Patented View
15830605 Nkp30 Receptor Targeted Therapeutics Patented View
15885550 Complexes Of Rna And Cationic Peptides For Transfection And For Immunostimulation Abandoned View
15885104 Complexes Of Rna And Cationic Peptides For Transfection And For Immunostimulation Abandoned View
16260032 Transgenic Strain Containing An Isolated Promoter Patented View
14910267 Means And Methods For The Generation Of Mammalian Producer Cells For The Production Of Recombinant Proteins Patented View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.